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AbstrAct
Introduction Shoulder pain is very common, with around 
70% of cases due to disorders of the rotator cuff. Despite 
widespread provision of physiotherapy, there is uncertainty 
about which type of exercise and delivery mechanisms are 
associated with best outcomes. There is also uncertainty 
around the long-term benefits and harms of corticosteroid 
injection therapy, which is often used in addition to 
physiotherapy. The Getting it Right: Addressing Shoulder 
Pain trial will assess the clinical and cost-effectiveness 
of individually tailored, progressive exercise compared 
with best practice advice, with or without corticosteroid 
injection, in adults with a rotator cuff disorder.
Methods and analysis We are conducting a large 
multicentre randomised controlled trial (2×2 factorial 
design). We will recruit adults ≥18 years with a new episode 
of shoulder pain attributable to a rotator cuff disorder as per 
British Elbow and Shoulder Society guidelines, not currently 
receiving physiotherapy or being considered for surgery, 
from at least eight UK National Health Service primary care-
based musculoskeletal and related physiotherapy services. 
Participants (n=704) will be randomised (centralised 
computer-generated 1:1:1:1 allocation ratio) to one of four 
interventions: (1) progressive exercise (≤6 physiotherapy 
sessions); (2) best practice advice (one physiotherapy 
session); (3) corticosteroid injection then progressive 
exercise (≤6 sessions) or (4) corticosteroid injection then 
best practice advice (one session). The primary outcome is 
the mean difference in Shoulder Pain and Disability Index 
(SPADI) total score at 12 months. Secondary outcomes 
are: pain and function SPADI subdomains; health-related 
quality of life (Five-Level version of the EuroQol EQ-5D-5L); 
sleep disturbance; return to activity; global impression of 
change; health resource use; out-of-pocket expenses; work 
disability. A parallel within-trial economic evaluation will be 
conducted. The primary analysis will be intention to treat.
Ethics and dissemination Research Ethics Committee 
approval (REC: 16/SC/0508) has been obtained. Results of 
the main trial and secondary outcomes will be submitted 
for publication in a peer-reviewed journal.
Trial registration number ISRCTN16539266; EudraCT 
number: 2016-002991-28.
IntroductIon
Shoulder pain is common. The prevalence of 
shoulder complaints in the UK is estimated at 
around 14%,1 increasing with age2 and highest 
in those aged 60 and above. Annually, around 
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Protocol
Strengths and limitations of this study
 ► The Getting it Right: Addressing Shoulder Pain trial 
is a large multicentre randomised controlled trial 
based in primary care and primary care interface 
services.
 ► Using a factorial design, we will cotest two 
interventions commonly used together in the 
management of rotator cuff disorders in primary care: 
progressive exercise delivered by a physiotherapist 
and corticosteroid injection. We will use a best-
practice advice session with a physiotherapist and 
no injection as the comparators.
 ► We want to assess which of these interventions, 
or combination of interventions, are most clinically 
and cost-effective. A parallel within-trial health 
economic analysis will also be conducted for the 
period of the trial.
 ► All outcome measures are patient reported. Due to 
the nature of the interventions, it is not possible to 
blind the study participants or care providers.
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1% of adults aged over 45 in primary care present with a 
new episode of shoulder pain,3 the most common attri-
bution being the rotator cuff which accounts for around 
70% of cases.3 Disorders of the rotator cuff are associated 
with substantial disability and pain and can have a signif-
icant impact on patient health and well-being, affecting 
an individual’s capacity to work and ability to perform 
daily tasks and social activities. Problems can persist for 
long periods with up to half of those who present for care 
continuing to have pain and/or functional disturbance 
for up to 2 years.4
The majority of shoulder pain is managed in primary 
care or at primary care interface musculoskeletal services 
by physiotherapists and general practitioners (GPs). The 
aim of treatment is to improve pain and function, and 
standard primary care options include rest, advice, anal-
gesia, non-steroidal anti-inflammatory drugs, referral to 
physiotherapy and corticosteroid injections.5 6 However, 
usual care can be highly variable. Furthermore, there are 
no recommended National Institute for Health and Care 
Excellence clinical guidelines for this area.
There is promising evidence from small, short-term 
trials7 8 that physiotherapist-prescribed exercise is effec-
tive for the treatment of rotator cuff disorders. However, a 
recent Cochrane review9 highlighted the lack of evidence 
about its long-term clinical and cost-effectiveness, despite 
the widespread provision of physiotherapy for these 
conditions. There is also uncertainty about which types 
of exercise and delivery mechanisms are associated with 
the best outcomes.7 8 10–12 This evidence is limited by 
problems in study design and choice of comparators.8 
There are also competing ideologies around which type 
of exercise programmes are considered most important. 
Resistance training to improve muscular strength, 
whether supervised or home based, has been identified 
as a core component of exercise for rotator cuff disor-
ders, although there is no evidence that any specific 
programme is superior.13 14 In a trial of strength training, 
duration, specificity of exercises, progression criteria 
and individualisation (ie, adjusting the programme to 
suit each participant) were also considered important.15 
In addition, little attention has been paid to the need 
for behavioural frameworks to enhance adherence to 
exercise, which is predominantly performed without 
physiotherapist supervision, and tackle unhelpful pain 
beliefs and behaviour.16
Corticosteroid injections are commonly used to reduce 
pain and inflammation associated with rotator cuff disor-
ders. There is good systematic review evidence17–19 that, 
in comparison with placebo, corticosteroid injections 
have a short-term benefit in the shoulder, as in other 
areas of the body. However, there are some concerns 
about their longer-term safety.20 The combination of 
injection and physiotherapy has intuitive appeal, with 
some evidence of an additive, but not interactive, short-
term effect.19 21–23 Due to the longer-term safety concerns, 
we believe that they require more study and hence have 
included unguided corticosteroid injections as part 
of our study design. Although the use of ultrasound to 
guide injections in primary care has become increasingly 
common, emerging evidence from the SUbacromial 
imPingement syndrome and Pain: a randomised 
cOntrolled Trial of exercise and injection (SUPPORT) 
trial (which looked at guided vs unguided injection) and 
others have demonstrated that it is no more effective than 
standard injection practice.4 24
The UK National Health Service (NHS) currently 
invests considerable resources on unproven therapies 
and must develop cost-effective, pragmatic methods of 
dealing with high-volume conditions such as rotator cuff 
disorders. The consequences of poor initial manage-
ment can lead to an increased likelihood of recurrent 
or persistent problems in older age and the need for 
surgery.5 Based on the existing evidence, we propose a 
definitive randomised controlled trial, using a facto-
rial design, to cotest two interventions commonly used 
together in the management of rotator cuff disorders in 
primary care: progressive exercise delivered by a phys-
iotherapist and corticosteroid injection. We will use a 
best-practice advice session with a physiotherapist and no 
injection as the comparators. We want to assess which of 
these interventions, or combination of interventions, are 
most clinically and cost-effective.
objectIves
The primary objectives of the Getting it Right: Addressing 
Shoulder Pain (GRASP) trial are to assess whether 
(1) an individually tailored progressive home exercise 
programme prescribed and supervised by a physiother-
apist provides greater improvement in shoulder pain 
and function at 12 months compared with a best prac-
tice advice session with a physiotherapist supported by 
high-quality self-management materials and whether (2) 
subacromial corticosteroid injection provides greater 
improvement in shoulder pain and function at 12 months 
compared with no injection.
Secondary objectives are to investigate if there are any 
differences at 8 weeks, 6 and 12 months in the following: 
shoulder pain; shoulder function; health-related quality 
of life; psychological factors; sleep disturbance; return 
to desired activities including work, social life and sport 
activities; patient global impression of change; adher-
ence to exercises, use of medication (prescribed and 
over the counter); time off work; health resource use 
(consultation with primary and secondary care) and 
additional out-of-pocket expenses. A parallel within-trial 
health economic analysis will also be conducted for the 
period of the trial.
Methods and analysIs
study design
The study will be a 2×2 factorial randomised controlled 
trial design (figure 1).
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Figure 1 Study flow diagram for GRASP trial. GRASP, Getting it Right: Addressing Shoulder Pain.
setting
The trial will be conducted across at least eight primary 
care-based musculoskeletal services and their related 
physiotherapy services in the UK NHS. These services 
treat people with a range of musculoskeletal conditions 
and are run by specialist practitioners including extend-
ed-scope physiotherapists and GPs with a specialist interest 
in musculoskeletal conditions. Sites will be chosen so they 
reflect a range of settings (urban and rural) and are able 
to deliver the trial interventions.
study participants
Participants will be recruited if referred by their GP or 
physiotherapist for treatment of a new episode, but not 
necessarily first episode of shoulder pain attributable to 
a rotator cuff disorder. Participants should be predomi-
nantly seeking treatment for one shoulder. People who 
self-refer directly to the service will also be assessed for 
eligibility as the typical route of referral can vary across 
services. The participants will not undergo diagnostic 
imaging such as MRI or ultrasound as a requirement of 
the trial, as this is generally not recommended in primary 
care.5
Eligibility
Patients will be eligible for this study if they are:
 ► aged 18 years and above;
 ► have a new episode of shoulder pain (ie, within the last 
6 months) attributable to a rotator cuff disorder (eg, 
cuff tendonitis, impingement syndrome, tendinopathy 
or rotator cuff tear) using the diagnostic criteria set 
out in the British Elbow and Shoulder Society (BESS) 
guidelines5 (online supplementary appendix 1);
 ► not currently receiving physiotherapy;
 ► not being considered for surgery;
 ► able to understand spoken and written English.
Patients will be excluded from participation in this study 
if:
 ► there is a history of significant shoulder trauma (eg, 
dislocation, fracture or full thickness tear requiring 
surgery);
 ► there is a neurological disease affecting the shoulder;
 ► they have other shoulder disorders (eg, inflammatory 
arthritis, frozen shoulder, glenohumeral joint 
instability) or have red flags consistent with the 
criteria set out in the BESS guidelines5;
 ► they have received corticosteroid injection or 
physiotherapy for shoulder pain in the last 6 months;
 ► they have contraindications to corticosteroid 
injection.
recruitment of participants, screening and eligibility 
assessment
Potential participants will attend their appointment 
in accordance with standard NHS procedures. The 
treating practitioner will undertake a clinical assess-
ment according to their usual practice. If a patient fulfils 
the criteria for a rotator cuff disorder, they will then be 
assessed to see whether they meet the GRASP eligibility 
criteria. Patients will be provided with a copy of the 
participant information sheet and asked if they wish to 
be considered for the trial. Those meeting the eligibility 
criteria and wishing to participate in the trial will then 
be approached for informed consent. Participants who 
do not meet the eligibility criteria, or who do not wish 
to participate, will receive standard NHS treatment. We 
will record anonymous information on the age and sex 
of those who decline to participate so that we can assess 
the generalisability of those recruited. The reasons for 
declining will also be recorded.
group.bmj.com on July 17, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
4 Hopewell S, et al. BMJ Open 2017;7:e018004. doi:10.1136/bmjopen-2017-018004
Open Access 
Table 1 Time-points at which the outcomes will be assessed
Outcome Measurement Time-point
Demographic Age, sex, height, weight, ethnicity, marital status, 
smoking, date of rotator cuff diagnosis, duration of 
symptoms, hand dominance, affected shoulder, current 
work status, level of education, place of residence, 
household income, state benefits
0
Primary
Pain and function SPADI37 38 13-item total scale 0, 8 weeks, 6 months, 12 months
Secondary
Pain SPADI37 38 five-item subscale 0, 8 weeks, 6 months, 12 months
Function SPADI37 38 eight-item subscale 0, 8 weeks, 6 months, 12 months
Health-related quality of life EQ-5D-5L score41 0, 8 weeks, 6 months, 12 months
Psychological factors Fear Avoidance Belief Questionnaire physical activity 
five-item subscale42
Pain Self-efficacy questionnaire (short form)43
0, 8 weeks, 6 months, 12 months
Sleep disturbance Insomnia Severity Index44 0, 8 weeks, 6 months, 12 months
Global impression of treatment Patient-rated Likert scale45 8 weeks, 6 months, 12 months
Return to desired activities Patient-reported return to desired activities, including 
work, social life and sport activities
8 weeks, 6 months, 12 months
Exercise adherence Patient-reported adherence to exercise 8 weeks, 6 months, 12 months
Medication usage Prescribed and over-the-counter medications, additional 
steroid injection
8 weeks, 6 months, 12 months
Work disability Sick leave (days) 8 weeks, 6 months, 12 months
Healthcare use NHS outpatient and community services (eg, GP, 
additional physical therapy)
NHS inpatient and day case (eg, radiography, MRI)
Private healthcare services
8 weeks, 6 months, 12 months
Out-of-pocket expenses Patient-related out-of-pocket expenses recording form 8 weeks, 6 months, 12months
EQ-5D-5L, Five-Level version of EuroQol Five Dimensions Questionnaire; GP, general practitioner; NHS, National Health Service; SPADI, 
Shoulder Pain and Disability Index.
Informed consent and baseline assessment
After participants have been assessed for eligibility, 
informed consent for participation in the trial will be 
sought by a research facilitator trained in good clin-
ical practice. Consent may take place during the initial 
appointment or may require a second appointment if 
participants require more time to consider the study. 
Participants will then be asked to complete the baseline 
assessment questionnaire that will record simple demo-
graphic information and baseline measurements for the 
primary and secondary outcomes (tables 1 and 2).
randomisation
Consented participants will be randomised to inter-
vention groups (1:1:1:1) by the site research facilitator 
using the centralised computer randomisation service 
provided by the Oxford Clinical Trials Research Unit. 
Randomisation will be computer-generated and strati-
fied by centre, age and gender, using a variable block size 
to ensure the participants from each site have an equal 
chance of receiving each intervention. Participants will 
be randomised to one of four physiotherapy-led interven-
tions:
 ► Progressive exercise programme: an individually 
tailored progressive home exercise programme 
prescribed and supervised by a physiotherapist 
involving up to six face-to-face sessions over 16 weeks.
 ► Best practice advice: one face-to-face session with 
a physiotherapist and a simpler home exercise 
programme supported by high quality self-
management materials.
 ► Progressive exercise programme (as described above), 
preceded by a corticosteroid injection.
 ► Best practice advice session (as described above), 
preceded by a corticosteroid injection.
blinding
Physiotherapists delivering the intervention and study 
participants will be informed of their treatment by the site 
research facilitator at the initial appointment and so will 
not be blinded to the treatment allocation. The trial statis-
tician and data entry personnel will also not be blinded to 
the treatment allocation. The remaining members of the 
central trial management team will be blinded to treat-
ment allocation until after the data analysis is complete.
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Table 2 Participant timeline
Time-point Pre randomisation Baseline 0–4 months
8-week 
follow-up
6-month 
follow-up
12-month 
follow-up
Enrolment
  Screening log ✓
  Eligibility confirmed ✓
  Informed consent ✓
  Randomisation ✓
Interventions
  Steroid injection (if randomised to) ✓
  Progressive exercise intervention (if 
randomised to)
✓
  Best practice advice intervention (if 
randomised to)
✓
Assessments
  Baseline questionnaire ✓
  Follow-up questionnaire ✓ ✓ ✓
  Follow-up reminders ✓ ✓ ✓
Interventions
Subacromial corticosteroid injection
The subacromial corticosteroid injection will be deliv-
ered prior to the progressive exercise or best practice 
advice intervention, predominately by extended-scope 
physiotherapists with appropriate postregistration qualifi-
cations in injection therapy working within a local patient 
group directive or equivalent. This reflects an increas-
ingly common practice in the NHS and ensures that the 
injections are delivered in the most cost-effective manner 
possible. The corticosteroid injection will be given as per 
its marketing authorisation and in accordance with its 
normal indication and therapeutic dosage (www. medi-
cines. org. uk/ emc/). The corticosteroid will be given 
together with local anaesthetic in one injection at the 
same time, or separately, depending on local treatment 
protocols at sites.
The corticosteroid injected will be either methylprednis-
olone acetate (up to 40 mg) or triamcinolone acetonide 
(up to 40 mg), depending on local treatment protocols 
at each site. These are the two routinely injected corti-
costeroids for shoulder pain; there is no clear evidence 
that either corticosteroid is more effective than another.19 
The local anaesthetic will be either 1% lidocaine (up to 
5 mL) or 0.5% bupivacaine hydrochloride (up to 10 mL), 
depending on local treatment protocols. We will only 
select sites that adhere to these prescribing boundaries. 
The choice and dose of corticosteroid and local anaes-
thetic (including volume) will be recorded for each 
participant in the trial data collection forms.
Participants will be advised to take care and avoid 
heavy lifting for 24–48 hours postinjection. Appointments 
will be coordinated so that participants typically receive 
their injection within 10 days of randomisation. Very 
occasionally, a second injection may be given after 6 weeks 
(but within 16 weeks of the patient being randomised), 
but will only be administered to those patients who 
receive good initial benefit from their first injection and 
who request further pain relief to facilitate their exer-
cises. Any participants that receive a second injection will 
have the dose, drug and date of administration recorded 
in their trial data collection form.
Progressive exercise intervention
Participants randomised to the progressive exercise 
programme will receive up to six sessions with a physio-
therapist over 16 weeks. These sessions will have a strong 
behavioural component to encourage adherence to the 
home exercise plan. A similar rationale has been used to 
good effect in other trials.15 25 This number of sessions, 
spread over this time, allows progression of the inten-
sity of exercise and sufficient time for a physiological 
response in the neuromuscular system to improve func-
tion. It also allows time to instigate longer term health 
behaviour change. Appointments will be coordinated so 
that participants typically start their first exercise session 
within 14 to 28 days of randomisation, as per local appoint-
ment availability. The initial session will last up to 60 min 
for assessment and starting the exercise programme, 
followed by up to five follow-up sessions of 20 to 30 min 
each. The physiotherapists will record the number of 
prescribed treatment sessions attended by each partici-
pant. The intervention has been designed to ensure that 
sufficient dose is delivered and to maximise compliance. 
Importantly, the intervention can be delivered within the 
current NHS commissioning paradigm.26 The progressive 
exercise programme consists of three phases of progres-
sion:
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Phase 1—Assessment and advice
Participants will be assessed and then given a self-man-
agement leaflet and tailored education, reassurance and 
advice on pain management and activity modification. 
They will also be given shoulder exercises to practise at 
home until their next session.
Phase 2—Progressive structured resistance training
Resistance exercises will be added that are highly struc-
tured and aim to improve the shoulder’s functional 
capacity. The exercises will be rehearsed in the physio-
therapy department and then practised at home. The 
progression of the volume and load of the resistance 
training will be based on existing guidelines27 and will 
take into account each individual’s capabilities and pref-
erences. The modified Borg scale of perceived exertion 
will be used to regulate the intensity of the resistance 
exercise.28 The load will initially be set at a moderate level 
to permit progression, enhance motivation and adher-
ence and reduce the possibility of symptom flare-up. The 
exercises will target the patient’s shoulder movement 
difficulties in a progressive way, consistent with expert 
consensus.29 Progression will be achieved by increasing 
the resistance/and or the number of repetitions. Hand 
weights or resistance bands will be used to add resis-
tance. Participants will be advised that some pain during 
the exercises is acceptable, provided the participant is 
happy and the symptoms resolve to an acceptable level 
after exercise.30 Patient preference for how each exercise 
is performed (where, when and position) will be agreed 
with the physiotherapist. The participants and therapists 
will negotiate an effective dose of exercise, progressively 
giving the participant overall control.
Phase 3—Patient-specific functional restoration
The final stage of training involves modifying the core 
resistance training exercises towards the specific strength-
ening movements required to achieve the functional 
goals of the individual.
Established behavioural change strategies31 will be 
used to maximise adherence to the exercise intervention. 
Implementation intentions and action planning tech-
niques32 have been found to be effective in improving 
physical activity levels. These intentions will form part 
of a behavioural exercise plan and exercise diary, which 
patients have reported to be helpful in promoting adher-
ence.33 The physiotherapists delivering the intervention 
will be trained in questioning techniques34 to elicit and 
address unhelpful beliefs about shoulder pain or exercise 
that may impede adherence.35
Best practice advice session
The participants randomised to the best practice advice 
session will receive a single face-to-face session with a 
physiotherapist, lasting up to 60 min. Appointments will 
be coordinated so that participants typically start their 
exercise session within 14 to 28 days of randomisation, 
as per local appointment availability. The best practice 
advice session will have substantially greater reliance 
on self-management. After a comprehensive shoulder 
assessment, the participants will be given a self-manage-
ment advice leaflet, tailored education, reassurance and 
self-management exercise advice, including advice on 
pain management and activity modification. They will 
also be given a simple set of self-guided exercises that can 
be progressed and regressed independently depending 
on their capability. The exercises will be designed using 
similar concepts to the progressive exercise intervention, 
such as increased resistance but there will be a simpler 
range of exercise options and will not be supervised. An 
exercise diary will be issued and a simplified exercise 
planner will be completed to encourage adherence with 
exercise. The best practice advice intervention will not be 
underpinned by the additional reassurance of follow-up 
physiotherapy appointments, which also enable more 
comprehensive behavioural aspects of the intervention 
through ongoing feedback and assistance with devel-
oping problem-solving over time.
The best practice advice session will be supported by 
high-quality patient self-management information and 
exercise videos available through a website and digital 
video disc. As possible low health literacy was a major 
consideration when developing materials, plain English 
and patient representative involvement was used to opti-
mise material accessibility. Using different media aims to 
make the information accessible and more appealing to a 
wide range of individuals36 and has been used successfully 
in other trials of painful musculoskeletal disorders.
A best practice advice session has been selected as the 
comparator because it is consistent with current clinical 
practice guidelines.5 6 This intervention also minimises 
the use of some physiotherapy treatments that, while 
commonly used, have evidence of no or minimal effect. 
In addition, many people find a single advice session and 
videos more beneficial as they do not have to come back 
to the hospital, take time off work or make carer arrange-
ments. This intervention may best serve commissioners, 
patients and clinicians in the long term.
Concomitant care
All participants will be advised to take over-the-counter 
analgesia as required, in accordance with the BESS guide-
lines.5 In addition, participants will be provided with advice 
on modifying activities that exacerbate symptoms and on 
sleeping positions. Participants may seek other forms 
of treatment during the trial but will be informed they 
should use usual routes (predominantly NHS referral) to 
do so. Additional treatments, including contact with their 
GP or other health professional, changes in medication, 
use of physical treatment and alternative therapies, will 
be recorded as a treatment outcome.
training and monitoring of intervention delivery
All physiotherapists delivering physiotherapy 
interventions will have access to a comprehensive inter-
vention manual and will be required to have undertaken 
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trial-specific training. The training will include compre-
hensive guidance on the theory and practical delivery 
of the trial interventions. A rigorous quality control 
programme will also be conducted to ensure interven-
tion fidelity. Quality assurance checks will be made by 
the trial team, who will observe treatment sessions and 
collect data on intervention delivery and number of treat-
ment sessions attended, including details about the core 
and adaptable components, to facilitate monitoring and 
reporting.
outcome measures
The primary outcome is shoulder pain and function 
at 12 months measured using the Shoulder Pain and 
Disability Index (SPADI) total score,37 38 which was devel-
oped to measure current shoulder pain and disability in 
an outpatient setting. A systematic review of outcome 
measurement sets for shoulder pain trials showed that 
SPADI is the most commonly used measure to assess pain 
and disability.39 It has good psychometric properties,40 is 
used widely in the field and can be completed using a 
postal questionnaire.
Secondary outcomes (table 1) will include: subdomains 
of the SPADI, which are pain measured using the SPADI 
five-item pain subscale37 38 and function measured using 
the SPADI eight-item disability subscale37 38; health-related 
quality of life measured using the five-level version of the 
well-validated EuroQol Five-Dimensional Questionnaire 
(EQ-5D)score41 ; psychological factors measured using 
the Fear Avoidance Belief Questionnaire (physical activity 
five-item subscale)42 and Pain Self-efficacy question-
naire (short form)43; sleep disturbance measured using 
the Insomnia Severity Index44; patient global impres-
sion of change45; return to desired activities, including 
work, social life and sport activities; patient adherence 
to exercise; any serious adverse events (SAEs); health 
resource use (consultation with primary and secondary 
care, prescribed and over-the-counter medication use, 
additional physiotherapy or injection use and hospital 
admission); additional out-of-pocket expenses and work 
absence (number of sickness days).
adverse events
Foreseeable adverse events occurring as a result of the 
trial intervention(s) will not be recorded as part of the 
trial. Instead, participants will be provided with infor-
mation on the potential adverse events resulting from 
exercise and corticosteroid injection (if applicable) as 
part of their treatment, including what they should do 
if they experience an adverse event, as would happen as 
part of standard NHS procedures. SAEs (defined as any 
unexpected medical occurrence than can result in death, 
is life threatening or results in hospitalisation or inca-
pacity) are likely to be very rare and are highly unlikely 
to occur as a result of either the exercise or corticosteroid 
injection therapy delivered in this trial. However, if an 
SAE arises from the participant’s enrolment in the trial to 
their final visit for their allocated intervention, standard 
procedures for recording and reporting SAEs will then 
apply.
Follow-up data collection
Measurements for the primary and secondary outcomes 
will be collected by postal or web-based questionnaires at 
8 weeks, 6 months and 12 months after randomisation. 
Participants will be asked to complete the questionnaire 
and return it to the GRASP study team in a prepaid enve-
lope or online as appropriate. For those who do not 
respond, at least one postal reminder will be sent. Tele-
phone follow-up will be used to contact those who do not 
respond to the reminder or who have not fully completed 
the returned questionnaire.
data management
All data will be processed according to the Data Protec-
tion Act 1998 and all documents will be stored safely in 
confidential conditions. All trial-specific documents, 
except for the signed consent form and follow-up contact 
details, will refer to the participant with a unique study 
participant number/code and not by name. Participant 
identifiable data will be stored separately from study data 
and in accordance with local procedures. All trial data 
will be stored securely in offices only accessible by swipe 
card by the central coordinating team staff in Oxford and 
authorised personnel.
sample size
The target sample size is 704 randomised participants 
(176 in each treatment arm). This is based on 90% power 
and 1% two-sided statistical significance to detect a mini-
mally clinically important difference of eight points on 
the SPADI total scale,37 assuming a baseline SD of 24.3 
(chosen as representative of the patient population46). 
This difference is the equivalent of a standardised 
effect size of 0.33, which requires a sample size of 550 
participants (Power Analysis and Sample Size 13, www. 
ncss. com). Allowing for a potential loss to follow-up at 
12 months of 20% inflates the sample size to 688. The 
sample size has been further inflated to take into account 
the potential for a small clustering by physiotherapist 
effect in the progressive exercise group. We use an intra-
cluster correlation coefficient (ICC) of 0.001, based on 
our experience with individually tailored physiotherapy 
interventions47 and expect each physiotherapist to treat 
approximately 20 participants in the progressive exer-
cise group. This leads to an inflation factor of f=1+(m−
1)*ICC=1+(20−1)*0.001=1.019 and increases the sample 
size to a total of 704 participants (176 per arm).
This sample size assumes no interaction effect and 
is powered for the two main effect comparisons: (1) 
progressive exercise versus best practice advice and (2) 
corticosteroid injection versus no injection when no inter-
action is present. However, this number of participants 
will also provide 80% power and 5% two-sided significance 
to detect an interaction standardised effect size of 0.35, 
if such an interaction effect does exist. The interaction 
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effect will be tested before the main effect comparisons 
are undertaken. It should be noted that a non-significant 
interaction effect does not preclude a smaller interaction 
that this study is not powered to detect.
statistical analysis
The primary statistical analysis will be carried out on the 
basis of intention to treat. The primary outcome measure 
is shoulder pain and function measured using the 
SPADI37 38 total score at 12 months postrandomisation. 
The scale is based on 13 questions, all scored on a 0–10 
numerical rating scale on which 10 is the worst score, with 
a five-item pain subscale and an 8-item disability subscale. 
The subscale items and total are summed and converted 
to a 0–100 scale, where a higher value denotes more pain 
and/or disability. There will be two main effect compar-
isons for this 2×2 factorial trial: (1) progressive exercise 
versus best practice advice and (2) subacromial cortico-
steroid injection versus no injection.
The analysis will be undertaken using longitudinal 
methods in a multivariable analysis with adjustment for 
the baseline SPADI score, stratification factors, important 
prognostic factors, clustering by physiotherapists and 
taking into account the multiple time-points. Statistical 
significance will be set at the 1% level and corresponding 
99% CIs will be reported for the primary outcome. 
For all other outcomes, 5% significance and 95% CIs 
will be reported. The data distribution will be formally 
assessed and if evidence for departure from normality is 
found, non-parametric techniques will be used with no 
adjustment (for example the Mann-Whitney test or the 
Kruskal-Wallis test). The secondary outcomes will be 
analysed using the same methodology as for the primary 
outcome.
Missing data
A linear mixed longitudinal model will be used to analyse 
all available data for the primary outcome. This method 
can take account of missing observations either due to 
missed visits or to a participant leaving the study prema-
turely, and can also be used when the participants are not 
all assessed at exactly the same time-point, as the exact 
time for each observation is used in the analysis. Missing 
data will be reported and summarised by treatment arm. 
The distribution of missing data will be explored to assess 
the assumption of data being missing at random. Multiple 
imputations will be used, if appropriate.
economic evaluation
A within-trial economic evaluation will be conducted in 
parallel with the assessment of the clinical effectiveness 
of the four intervention groups. The factorial design will 
also allow the economic evaluation of the two primary 
comparisons. Health-related quality of life will be esti-
mated using the EQ‐5D-5L.48 The responses to the EQ-5D 
will be converted into multiattribute utility scores using 
an approved ‘cross-walk’ to the three-level instrument 
and its established utility algorithm for the UK,49 50 or 
the new UK-approved five-level utility tariff, if published. 
The economic evaluation will be conducted from a UK 
NHS and Personal Social Services perspective51 and will 
compare the costs and outcomes at 12-month follow-up 
using the trial data. The outputs of the economic evalua-
tion will be presented in terms of expected incremental 
cost-effectiveness ratios. Cost-effectiveness acceptability 
curves will be generated via non-parametric bootstrapping 
and displayed graphically, alongside cost-effectiveness 
planes and expected net benefit statistics. Probabilistic 
sensitivity analyses will be performed to explore the 
implications of parameter uncertainty on the incre-
mental cost-effectiveness ratios. Subgroup analysis using 
predefined subgroups will investigate potential treatment 
moderators such as age, sex and other baseline charac-
teristics for which cost effectiveness is predicted to be 
different.
The at-the-margins approach (without interactions) 
may treat the factorial trial as though it were two overlap-
ping two-arm randomised trials and may effectively ignore 
the factorial design as it assumes that factors have purely 
additive effect. If there is no interaction, ignoring interac-
tions is statistically efficient, answering two questions with 
the same sample size required for one. However this form 
of analysis gives biased or misleading results if there is any 
interaction. Regression analysis provides a convenient 
way to evaluate interactions and main effects. Including 
covariates within regression facilitates adjustment for 
baseline imbalance, which may be particularly important 
for factorial trials. For the purpose of the economic eval-
uation, we will investigate the possible interactions with 
quality-adjusted life-years and costs. The distribution of 
costs and benefits and correlation between costs and 
effects will also be considered. If factors are thought to 
have a multiplicative effect, a general linear model may 
be appropriate in transformed data.
ethIcs and dIsseMInatIon
Ethics approval was obtained from the Berkshire B 
Research Ethics Committee (REC: 16/SC/0508) (22 
November 2016), approved by the UK Competent 
Authority, the Medicines and Healthcare Regulatory 
Agency (MHRA) (EuDRACT: 2016-002991-28) and 
prospectively registered (ISRCTN: 16539266). A data 
monitoring and ethics committee has been appointed 
to independently review data on safety, protocol adher-
ence and recruitment to the trial in accordance with the 
DAta MOnitoring Committees: Lessons, Ethics, Statistics 
(DAMOCLES) charter. Direct access to research data will 
be granted to authorised representatives of the Sponsor 
(University of Oxford), regulatory authorities or the host 
institution for monitoring and/or auditing of the study 
to ensure compliance with regulations. Summary results 
data will be included on the EudraCT database within 
12 months of the end of the trial. General release will 
be 5 years after the end of the trial, to allow the investi-
gators sufficient time to complete and report additional 
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analyses of the data set. Trial findings will inform NHS 
clinical practice for the management of patients with a 
rotator cuff disorder and its results will be published as 
a monograph as part of the National Institute of Health 
Research Health Technology Assessment journal series 
and in a high-impact open-access journal, in accor-
dance with Consolidated Standards of Reporting Trials 
(CONSORT) and Template for Intervention Description 
and Replication (TIDieR52) guidelines. Trial materials 
will be made available via the trial website on completion 
of the trial. Prior to formal publication, we will inform 
the participants of the trial results. Participants will be 
asked if and how they would like to be informed of the 
results as part of the consent process.
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